Shares of IDEXX Laboratories, Inc. (IDXX, Financial), a leader in veterinary diagnostics, rose on evidence of improving organic growth and excitement around its launch of CatalystOne, a new diagnostic platform. During its most recent quarter, IDEXX's organic revenue growth improved from mid-single digits to 11%, helped by strong instrument sales and accelerating volumes for the associated consumables. We believe that recent innovations in its diagnostic products, data management capabilities, and its go-to-market strategy have positioned IDEXX to continue recent market share gains and to significantly accelerate its revenue growth.
From Baron Funds' first quarter 2014 commentary.
